Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 13 June 2018

Indication(s)

- NovoMix 30 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 30 FlexPen 100 units/ml suspension for injection in pre-filled pen


NovoMix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.



- NovoMix 50 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 50 FlexPen 100 units/ml suspension for injection in pre-filled pen


NovoMix 50 is indicated for treatment of diabetes mellitus in adults.



- NovoMix 70 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 70 FlexPen 100 units/ml suspension for injection in pre-filled pen


NovoMix 70 is indicated for treatment of diabetes mellitus in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000308
Orphan designation No
Date First Approved 01-08-2000
Type Medicinal product subject to medical prescription
Marketing authorisation holder Novo Nordisk A/S